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Over the last century and a half, the world’s
population has grown from one billion to almost
six billion, and the time required to circumnavi-
gate the globe has decreased from 365 days to
fewer than 3. Currently, 1.4 million persons
travel internationally by air every day. The speed
and volume of international travel are cited by
the Institute of Medicine as principal factors
contributing to the global emergence of infectious
diseases. This panel assessed the effect of travel
on emerging infections from the perspectives of
both industrialized (Jay Keystone) and develop-
ing countries (David Shlim), discussed the role of
vaccination in preventing travel-related infec-
tions (Robert Steffen), and explored unique
health issues associated with travel into space
(David Shlim and Thomas Marshburn, National
Aeronautics and Space Administration [NASA]).
Travel and the Spread of Emerging
Infectious Diseases
In the past decade, international travel has
grown dramatically to the point where more than
500 million travelers cross international borders
annually by commercial aircraft alone. Mass
migrations of refugees, workers, and displaced
persons have led to a steady growth of urban
centers at the expense of rural areas. These
population movements have been ideal conduits
for the global spread of new and reemerging
infectious diseases. Virtually any place in the
world can be reached within 36 hours, less than
the incubation period for most infectious
diseases. Infectious agents can spread from
person to person directly or to vectors at the
traveler’s destination. Vehicles of human trans-
port, such as aircraft and ships, also transport the
infectious agent and its vector. In addition, mass
migrations have facilitated the rapid and
immediate spread of communicable disease
among refugees and displaced persons.
If travelers are responsible for the spread of
infectious agents, they are also ideal sentinels for
the arrival of an infectious agent in a new
community. In 1969, the first documented
outbreak of Lassa fever was noted among
American missionaries in Lagos, Nigeria. In
1992, two Peace Corps volunteers contracted
neuroschistosomiasis; a subsequent investiga-
tion confirmed that Lake Malawi was an
important source for the transmission of
Schistosoma haematobium. More recently, chlo-
roquine-resistant Plasmodium vivax was docu-
mented for the first time in North Africa in U.S.
Army troops returning from Somalia.
These and many other examples show that
travel is instrumental in the spread of new and
reemerging infectious diseases. As international
travel grows by more than 10% per year and
major population shifts continue because of
political, economic, and social instability, public
health agencies will have to focus their infectious
disease surveillance programs on travelers,
migrants, and the vehicles of transport.
Recognition that travelers are important sentinels
for emerging infectious diseases has stimulated the
International Society of Travel Medicine and the
Centers for Disease Control and Prevention to carry
out a joint surveillance project, Geosentinel, in 22
travel clinics around the world.
Vaccinating Travelers
Vaccination is only one of several strategies of
prophylaxis in travel medicine. Selection of
immunizations should be based on requirements
and on risk for infection. According to the
International Health Regulations, many countries
require proof of yellow fever vaccination on the
International Certificate of Vaccination. The
revised International Health Regulations, to be
submitted to the World Health Assembly next year,
will likely maintain this requirement. Addition-
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ally, a few countries still require proof of vac-
cination against cholera, diphtheria, and meningo-
coccal disease under specific circumstances.
Recommended immunizations often are more
important for travelers’ health than the required
or routine ones. The most frequent vaccine-
preventable infection in travelers to developing
countries is hepatitis A, with an average
incidence rate of 0.3% per month in susceptible
persons; in high-risk backpackers or foreign-aid
volunteers, this rate is 2.0%. The World Health
Organization and many national expert groups
recommend that all travelers visiting developing
countries be immunized against hepatitis A.
Several other immunizations are recommended
for special risk groups. Hepatitis B is a problem
among expatriates, particularly if they live close
to the native population or engage in high-risk
behavior (e.g., unprotected casual sex or
intravenous drug use); rabies is also a problem,
with approximately 0.2% to 0.4% of long-term
residents bitten by animals each month—
travelers to selected geographic regions with high
endemicity (Southeast Asia) and exposure risk
profiles warrant rabies vaccination; typhoid fever
(often diagnosed among travelers to the Indian
subcontinent, North and West Africa—except
Tunisia—and Peru) poses a higher risk in long-
term residents and in those who consume food
and beverages prepared under substandard
hygienic conditions (estimated incidence 0.03% to
0.003% per month); anecdotally, meningococcal
disease, Japanese encephalitis, and tick-borne
encephalitis have been reported in travelers
(monthly incidence less than one per million
travelers); immunizations against cholera and
tuberculosis are only rarely recommended.
In the not-too-distant future, travelers will be
offered a variety of oral vaccines against
pathogens causing travelers’ diarrhea, including
all enterotoxigenic Escherichia coli as well as
Campylobacter and Shigella. Additionally, im-
munization against Lyme disease and dengue
fever will be available within the next years;
vaccines against malaria and AIDS, the
infections causing most death in travelers, are
much further in the future.
Emerging Diseases in a Developing
Country: Observations from a Travel
Medicine Clinic
The CIWEC Clinic Travel Medicine Center
was the world’s first self-supporting destination
travel medicine clinic. Started in 1982 to provide
western medical care for expatriates and tourists in
Nepal, the clinic has set a standard for investigating
disease risks for tourists in a developing country.
Nepal (population 22 million, resident
foreign population 3,000) has an annual influx of
approximately 250,000 non-Indian tourists a
year. The Travel Medicine Center is situated in
the capital, Kathmandu, through which 90% of
tourists enter and exit the country; a high
percentage of expatriates and tourists use the
clinic for medical care, creating a favorable
situation for health-risk studies.
Emerging diseases can be divided into three
categories: 1) truly new diseases, such as
diarrhea caused by Cyclospora; 2) newly noted or
increasing diseases, such as meningococcal
meningitis and Japanese encephalitis; and 3)
unexplained illnesses, such as a cluster of cases of
sudden death among young trekkers in teahouses.
The Travel Medicine Center has made it possible
to observe all three categories. Most of the above
conditions would likely have remained unnoticed
and unreported were it not for the presence of a
clinic focused on the health risks of foreigners in
Nepal.
The value of a research-oriented travel
medicine center in Kathmandu extends beyond
the borders of Nepal. Research into diarrheal
disease, hepatitis, typhoid fever, rabies
immunoprophylaxis, and altitude illness has
been relevant to other locations. Specific disease
risks for travelers to Nepal have been carefully
defined. Clinics in other developing countries
should be identified, and similar data gathering
and observations should be encouraged.
Travel Medicine in the 21st Century: NASA
Perspectives
Space travel entails unique circumstances
that influence the health of astronauts, most
notably, the limitations imposed by zero-gravity
environments. The impact of weightlessness on
human physiology is substantial and affects various
body systems: neurologic, psychologic, vestibular,
cardiovascular, musculoskeletal, endocrine, hema-
tologic, and immunologic. Prominent sequelae of
prolonged weightlessness may include profound
motor weakness and 1% to 2% loss of mineralized
bone for each month in orbit; these effects can be
countered by maintaining a vigorous daily
exercise program while in orbit. In addition,
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documented a decrease in cell-mediated
immunity among astronauts spending ex-
tended time in space.
Environmental stressors (prolonged expo-
sure to increased temperatures, high-velocity
travel [17,000 miles per hour], and prolonged
confinement to limited physical space) may also
affect the health of space travelers. The space
environment also challenges the growth of
microorganisms. Increased antimicrobial resis-
tance has been noted among E. coli and
Staphylococcus aureus bacteria in space, and
fungal overgrowth can be a problem because of
changes in humidity and pockets of increased
condensation aboard spacecraft and space stations.
The primary strategies used by NASA to
prevent health-related mishaps associated with
space travel include selecting exceptionally fit,
healthy crew members and imposing preflight
protective quarantine. Access to the astronauts is
restricted to family members beginning 10 days
before departure, and a strict 7-day prelaunch
quarantine is imposed.
Thus far, infectious diseases have rarely been
an important problem at NASA; launch delays
due to infectious diseases have occurred in only
two Apollo flights and one shuttle mission. One
instance of infectious prostatitis in an astronaut on
the MIR space station resulted in the premature
termination of his stay. Recent forays into long-
term habitation in space such as those aboard MIR
(3 to 6 months) will provide new insights into the
feasibility of extended space travel and human
colonization beyond our planet.